Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
13 Octubre 2023 - 7:00AM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology, today announces that experts recommend the
use of blood volume analysis (BVA) to guide optimal treatment in
heart failure patient at two Scientific Sessions held during the
Heart Failure Society of America Annual Scientific Meeting on
October 8th & 9th, 2023, at the Huntington Convention Center in
Cleveland, OH.
Highlights from the sessions included:
- Expert panelists from Duke Clinical
Health, the Mayo Clinic, and Medstar Hospital system all presented
case studies and peer-reviewed data showing BVA to be an essential
diagnostic tool for their practice
- BVA was identified as a unique tool
to determine intravascular volume profiles, guiding the most
appropriate individualized patient management
- Implementing BVA led to improved
patient outcomes, decreases in hospital length of stay, and
provided positive return on investment for panelists sharing their
clinical experience
- Daxor’s technology was also
featured in an expert panel on Innovative Devices for Heart Failure
Management highlighting the added benefit that it is now available
and cleared for use by FDA
Historically, clinicians have made care
decisions based on proxy pressure-based hemodynamics assessments,
but data show pressure is often a poor proxy for volume, and
optimal volume care is the cornerstone of effective heart failure
congestion care. The first session, titled, “Managing Congestion:
Targeting Pressure vs. Volume,” was co-moderated by Dr. Arvind
Bhimaraj, Houston Methodist DeBakey Heart and Vascular and Dr.
Marat Fudim, Duke University Health. Panel members including Dr.
Wayne Miller, Mayo Clinic, Dr. Brian Howard, Wellstar, and
Stephanie Barnes, CHFN, Duke University Hospital all called for the
routine use of BVA to improve heart failure care.
Dr. Miller stated, “If you don’t measure, you
don’t know volume.” Dr. Miller also highlighted the importance of
knowing the red blood cell volume to optimize fluid management
which is a key metric of Daxor’s BVA diagnostic blood test.
Clinical use of blood volume analysis was
highlighted through patient case studies presented by Dr. Howard
and Stephanie Barnes. Dr. Howard conveyed, “BVA is appropriate for
both inpatient and outpatient use when volume status is unclear,
the patient has worsening renal function, to improve heart failure
outcomes, and when you need more information than what physical
exam or labs provide.” Stephanie Barnes added, “Implementing BVA
improves patient outcomes, decreases hospital length of stay, and
is a wonderful return on investment.”
The second session, titled, “Device Innovation
to Manage Congestion in Heart Failure,” discussed the latest
methods to recognize and treat congestion in heart failure. Panel
member Dr. Maria Rosa Constanzo, Midwest Cardiovascular Institute,
stated, “assessment of congestion is complex,” and stressed the
importance of monitoring congestion early before hospitalization.
Dr. Costanzo added, “BVA is helpful and gives you total blood, red
blood cell, plasma volume so you can phenotype the patient’s volume
status in a more precise way.”
“We are thrilled that our diagnostic blood test
was recognized for its importance amongst these groups of esteemed
experts,” said Michael Feldschuh, Daxor’s CEO and President.
“Clinical demand for our diagnostic continues to grow. Our
diagnostic has significant value for providers and informs
clinicians with critical information to manage and treat volume
derangements, so patients feel better, get out of the hospital
faster, and have better results in terms of mortality and
readmission when compared to those who did not receive BVA-guided
care.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024